Free tool
Drug Trial Radar: Gastroenterology and liver
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
158
Completed, industry sponsors, Gastroenterology and liver, Phase 3
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed158
158 trials
Showing 1 to 25, recently updated first.
- Linerixibat Long-term Safety, and Tolerability StudyPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT04167358 · 242 participants · Start Jul 8, 2020 · Primary completion Sep 30, 2026
Drug: Linerixibat · For: Cholestasis
Sites: Sacramento, California; West Hollywood, California; Miami, Florida · 94 sites in all
- Clinical Trial to Evaluate the Safety and Efficacy of DW4421 in Patients With Erosive Reflux DiseasePivotal-lookingCompleted
Daewon Pharmaceutical Co., Ltd.Industry
NCT07931521 · 328 participants · Start Nov 17, 2025 · Primary completion Aug 31, 2026
Drug: DW4421 20mg; DW4421 40mg and 1 more · For: Erosive Reflux Disease; GERD (Gastroesophageal Reflux Disease)
Sites: Seoul, South Korea
- A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Participants With Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD)Pivotal-lookingCompleted
Cinclus Pharma Holding ABIndustry
NCT07037875 · 523 participants · Start Sep 11, 2025 · Primary completion Sep 28, 2026
Drug: Linaprazan glurate 50 mg Twice Daily (BID); Linaprazan Glurate 50 mg Once Daily (QD) and 1 more · For: GERD (Gastroesophageal Reflux Disease)
Sites: Dupnitsa, Bulgaria; Gorna Oryahovitsa, Bulgaria; Sliven, Bulgaria · 87 sites in all
- The Plecanatide Irritable Bowel Syndrome With Constipation Safety and Efficacy Study (IBS-C)Pivotal-lookingCompleted
Bausch Health Americas, Inc.Industry
NCT02387359 · 1,054 participants · Start Dec 2014 · Primary completion Dec 2016
Drug: Plecanatide; Placebo · For: Irritable Bowel Syndrome Characterized by Constipation
Sites: Athens, Alabama; Birmingham, Alabama; Dothan, Alabama · 155 sites in all
- Open Label Safety Study of Tradipitant in Idiopathic and Diabetic GastroparesisPivotal-lookingCompleted
Vanda PharmaceuticalsIndustry
NCT06836557 · 17 participants · Start Jan 9, 2024 · Primary completion Mar 30, 2026
Drug: Tradipitant · For: Idiopathic Gastroparesis; Diabetic Gastroparesis; Gastroparesis
Sites: Leuven, Belgium; Liège, Belgium; Leipzig, Germany
- A Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Non-Erosive Reflux DiseasePivotal-lookingCompleted
Braintree LaboratoriesIndustry
NCT05587322 · 788 participants · Start Sep 6, 2022 · Primary completion Oct 13, 2023
Drug: BLI5100; Placebo · For: Non-erosive Reflux Disease
Sites: Huntsville, Alabama; Peoria, Arizona; Phoenix, Arizona · 112 sites in all
- Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis.Pivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT05267613 · 53 participants · Start Jul 1, 2022 · Primary completion Aug 10, 2026
Drug: Nexium 20mg; Nexium 10mg · For: Erosive Esophagitis
Sites: Mobile, Alabama; Sacramento, California; Miami, Florida · 41 sites in all
- Study Evaluating Pantoprazole in Children With Gastroesophageal Reflux Disease (GERD)Pivotal-lookingCompleted
Wyeth is now a wholly owned subsidiary of PfizerPfizer (PFE)
NCT00300755 · 60 participants · Start May 2006 · Primary completion Apr 2008
Drug: pantoprazole sodium enteric-coated spheroid · For: Gastroesophageal Reflux
Sites: Mobile, Alabama; Phoenix, Arizona; Oakland, California · 43 sites in all
- Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic GastroparesisPivotal-lookingCompleted
Vanda PharmaceuticalsIndustry
NCT04028492 · 979 participants · Start Aug 20, 2019 · Primary completion Feb 21, 2025
Drug: Tradipitant; Placebo and 1 more · For: Idiopathic Gastroparesis; Diabetic Gastroparesis; Gastroparesis
Sites: Birmingham, Alabama; Peoria, Arizona; Little Rock, Arkansas · 36 sites in all
- Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 YearsPivotal-lookingCompleted
ArdelyxIndustry
NCT05643534 · 180 participants · Start Nov 15, 2022 · Primary completion Aug 20, 2026
Drug: Tenapanor 50 MG; Tenapanor 25 mg bid and 1 more · For: Irritable Bowel Syndrome With Constipation (IBS-C)
Sites: Foley, Alabama; Tucson, Arizona; Little Rock, Arkansas · 39 sites in all
- Saroglitazar Magnesium for Treatment of Primary Biliary CholangitisPivotal-lookingCompleted
Zydus Therapeutics Inc.Industry
NCT05133336 · 196 participants · Start Apr 1, 2022 · Primary completion Apr 30, 2025
Drug: Saroglitazar Magnesium 1 mg; Saroglitazar Magnesium 2 mg and 1 more · For: Primary Biliary Cholangitis
Sites: Birmingham, Alabama; Tucson, Arizona; Los Angeles, California · 57 sites in all
- A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Japanese Participants With Eosinophilic GastroenteritisPivotal-lookingCompleted
CelgeneBristol Myers Squibb (BMY)
NCT05214768 · 48 participants · Start Mar 4, 2022 · Primary completion Jul 2, 2024
Drug: CC-93538; Placebo · For: Eosinophilic Gastroenteritis
Sites: Gifu, Japan; Himeji-shi, Japan; Nishinomiya, Japan · 25 sites in all
- Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN)Pivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT04950127 · 238 participants · Start Aug 27, 2021 · Primary completion Oct 28, 2024
Drug: Linerixibat; Placebo · For: Pruritus
Sites: Erlangen, Germany; Münster, Germany; Cambridge, United Kingdom · 5 sites in all
- A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.Pivotal-lookingCompleted
IpsenIndustry
NCT06383403 · 92 participants · Start Jul 9, 2024 · Primary completion Jun 16, 2026
Drug: Elafibranor · For: Primary Biliary Cholangitis
Sites: Coronado, California; Los Angeles, California; Sacramento, California · 60 sites in all
- Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC)Pivotal-lookingCompleted
Gilead SciencesGilead Sciences (GILD)
NCT06060665 · 96 participants · Start Sep 5, 2023 · Primary completion May 6, 2026
Drug: Seladelpar 10 mg; Placebo · For: Primary Biliary Cholangitis
Sites: Chandler, Arizona; Pasadena, California; Sacramento, California · 45 sites in all
- Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic EsophagitisPivotal-lookingCompleted
CelgeneBristol Myers Squibb (BMY)
NCT04991935 · 367 participants · Start Aug 9, 2022 · Primary completion Aug 14, 2025
Drug: CC-93538 · For: Eosinophilic Esophagitis
Sites: Birmingham, Alabama; Phoenix, Arizona; Scottsdale, Arizona · 167 sites in all
- Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-CPivotal-lookingCompleted
AbbVieAbbVie (ABBV)
NCT04166058 · 381 participants · Start Nov 19, 2019 · Primary completion Jun 5, 2025
Drug: Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 and LIN-MD-64 completers); Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers) · For: Irritable Bowel Syndrome With Constipation; Functional Constipation
Sites: Birmingham, Alabama; Foley, Alabama; Saraland, Alabama · 72 sites in all
- Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE)Pivotal-lookingCompleted
Regeneron PharmaceuticalsRegeneron (REGN)
NCT04394351 · 102 participants · Start Sep 1, 2020 · Primary completion Jun 2, 2022
Drug: Dupilumab; Matching Placebo · For: Eosinophilic Esophagitis (EoE)
Sites: Phoenix, Arizona; Little Rock, Arkansas; Los Angeles, California · 27 sites in all
- A Study to Evaluate the Long-Term Safety of BLI5100 in Patients With Gastroesophageal Reflux DiseasePivotal-lookingCompleted
Braintree LaboratoriesIndustry
NCT05890001 · 400 participants · Start Apr 5, 2023 · Primary completion Oct 8, 2024
Drug: BLI5100 · For: Non-erosive Reflux Disease; Erosive Esophagitis
Sites: Huntsville, Alabama; Phoenix, Arizona; Tucson, Arizona · 60 sites in all
- 24-Week Induction Study of APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE 3)Pivotal-lookingCompleted
Ellodi Pharmaceuticals, LPIndustry
NCT05634746 · 218 participants · Start Dec 29, 2022 · Primary completion Aug 12, 2024
Drug: APT-1011; Placebo oral tablet · For: Eosinophilic Esophagitis
Sites: Dothan, Alabama; Mobile, Alabama; Scottsdale, Arizona · 60 sites in all
- Compound Sodium Alginate Double Action Chewable Tablet Symptomatic Relief StudyPivotal-lookingCompleted
Reckitt Benckiser Healthcare (UK) LimitedIndustry
NCT01869491 · 1,107 participants · Start Jun 5, 2013 · Primary completion May 2014
Drug: Compound Sodium Alginate Double Action Chewable Tablets; Matching placebo tablets · For: Gastroesophageal Reflux Disease; Dyspepsia
Sites: Beijing, China; Shanghai, China
- Compound Sodium Alginate Double Action Chewable Tablets 4-hour Esophageal pH Study in GERD PatientsPivotal-lookingCompleted
Reckitt Benckiser Healthcare (UK) LimitedIndustry
NCT01872897 · 45 participants · Start Jul 2, 2013 · Primary completion Dec 2013
Drug: Sodium Alginate Double Action Chewable Tablets; Placebo · For: Gastroesophageal Reflux Disease
Sites: Shanghai, China
- A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Participants With Eosinophilic EsophagitisPivotal-lookingCompleted
CelgeneBristol Myers Squibb (BMY)
NCT04753697 · 430 participants · Start Feb 22, 2021 · Primary completion Jan 11, 2024
Drug: CC-93538 · For: Eosinophilic Esophagitis
Sites: Birmingham, Alabama; Tuscaloosa, Alabama; Phoenix, Arizona · 212 sites in all
- An Extension Study to Evaluate Maintenance of Efficacy and Long-term Treatment Effect of Oral Budesonide Suspension (OBS) in Adults and Adolescents With Eosinophilic Esophagitis (EoE)Pivotal-lookingCompleted
ShireTakeda (TAK)
NCT02736409 · 219 participants · Start Apr 1, 2016 · Primary completion Nov 12, 2019
Drug: Oral Budesonide Suspension (OBS); Placebo · For: Eosinophilic Esophagitis (EoE)
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 62 sites in all
- A Study in Adolescents and Adults With Eosinophilic Esophagitis (EoE) Measuring Histologic Response and Determine if Reduction in Dysphagia is AchievedPivotal-lookingCompleted
ShireTakeda (TAK)
NCT02605837 · 318 participants · Start Dec 7, 2015 · Primary completion Jan 24, 2019
Drug: Oral Budesonide Suspension (OBS); Placebo · For: Eosinophilic Esophagitis (EoE)
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 77 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.